Impact of Dexamethasone Responsiveness on Long Term Outcome in Patients with Newly Diagnosed Multiple Myeloma

Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates of 50-60%. It is unclear whether steroid responsiveness reflects any biological characteristic that impacts long-term out...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Sinha, Shirshendu, Rajkumar, S. Vincent, Lacy, Martha Q., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Dingli, David, Kyle, Robert A., Gertz, Morie A., Kumar, Shaji
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2864312/
https://ncbi.nlm.nih.gov/pubmed/19958361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.08023.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares